|
|
| (8 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| − | {{tp|p=32308988|t=2020. The use of simulation to prepare and improve responses to infectious disease outbreaks like COVID-19: practical tips and resources from Norway, Denmark, and the UK |pdf=|usr=}}
| + | see [[Epidemiology]] |
| − | {{tp|p=32282887|t=ä. Understanding the Dynamics of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32334894|t=ä. A state overview of COVID19 spread, interventions and preparedness |pdf=|usr=}}
| + | |
| − | {{tp|p=32360746|t=2020. Weathering COVID-19 Storm: Successful Control Measures of Five Asian Countries |pdf=|usr=}}
| + | |
| − | {{tp|p=C7151256|t=ä. Community-based prevention and control of COVID-19: Experience from China |pdf=|usr=}}
| + | |
| − | {{tp|p=32301478|t=2020. Counting Coronavirus Disease 2019 (COVID-19) Cases: Case Definitions, Screened Populations and Testing Techniques Matter |pdf=|usr=}}
| + | |
| − | {{tp|p=32176272|t=ä. Estimation of Coronavirus Disease 2019 (COVID-19) Burden and Potential for International Dissemination of Infection From Iran |pdf=|usr=}}
| + | |
| − | {{tp|p=32150748|t=ä. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application |pdf=|usr=}}
| + | |
| − | {{tp|p=32023340|t=ä. Reporting, Epidemic Growth, and Reproduction Numbers for the 2019 Novel Coronavirus (2019-nCoV) Epidemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32259195|t=ä. Intersecting U S Epidemics: COVID-19 and Lack of Health Insurance |pdf=|usr=}}
| + | |
| − | {{tp|p=32343764|t=ä. Health Insurance Status and Risk Factors for Poor Outcomes With COVID-19 Among U S Health Care Workers: A Cross-sectional Study |pdf=|usr=}}
| + | |
| − | {{tp|p=32240293|t=ä. Collision of the COVID-19 and Addiction Epidemics |pdf=|usr=}}
| + | |
| − | {{tp|p=32240291|t=ä. When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis |pdf=|usr=}}
| + | |
| − | {{tp|p=32240283|t=ä. An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32298421|t=ä. Pandemic Surge Models in the Time of Severe Acute Respiratory Syndrome Coronavirus-2: Wrong or Useful?|pdf=|usr=}}
| + | |
| − | {{tp|p=32289150|t=2020. Caution Warranted: Using the Institute for Health Metrics and Evaluation Model for Predicting the Course of the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32175421|t=2020. Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32287518|t=2020. Rapid surveillance of COVID-19 in the United States using a prospective space-time scan statistic: Detecting and evaluating emerging clusters |pdf=|usr=}}
| + | |
| − | {{tp|p=32266703|t=ä. Why Only Test Symptomatic Patients? Consider Random Screening for COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32249361|t=ä. A Simple Decision Analysis of a Mandatory Lockdown Response to the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32362799|t=ä. Composite Monte Carlo decision making under high uncertainty of novel coronavirus epidemic using hybridized deep learning and fuzzy rule induction? |pdf=|usr=}}
| + | |
| − | {{tp|p=32331618|t=2020. COVID-19: Mitigation or suppression?|pdf=|usr=}}
| + | |
| − | {{tp|p=32331787|t=ä. Comparative Global Epidemiological Investigation of SARS-CoV-2 and SARS-CoV Diseases Using Meta-MUMS Tool Through Incidence, Mortality, and Recovery Rates |pdf=|usr=}}
| + | |
| − | *[https://lawliberty.org/virus-deaths-in-democratic-versus-republican-states/ 3-fold relative risk in democrative vs conservative states]
| + | |
| − | {{tp|p=32279479|t=2020. Asymptomatic Patients with Novel Coronavirus Disease (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32328220|t=ä. A Proposed Process for Risk Mitigation During the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32327306|t=ä. New paths for sustainable solutions to tackle global and emerging infectious threats |pdf=|usr=}}
| + | |
| − | {{tp|p=32375234|t=2020. Temperature Decreases Spread Parameters of the New Covid-19 Case Dynamics |pdf=|usr=}}
| + | |
| − | {{tp|p=32182724|t=2020. Understanding Unreported Cases in the COVID-19 Epidemic Outbreak in Wuhan, China, and the Importance of Major Public Health Interventions |pdf=|usr=}}
| + | |
| − | {{tp|p=32342242|t=ä. Outbreak dynamics of COVID-19 in China and the United States |pdf=|usr=}}
| + | |
| − | {{tp|p=32188819|t=2020. Analysis of COVID-19 infection spread in Japan based on stochastic transition model |pdf=|usr=}}
| + | |
| − | {{tp|p=32321904|t=2020. Asymptomatic carriers of COVID-19 as a concern for disease prevention and control: more testing, more follow-up |pdf=|usr=}}
| + | |
| − | {{tp|p=32295793|t=2020. To monitor the COVID-19 pandemic we need better quality primary care data |pdf=|usr=}}
| + | |
| − | {{tp|p=32375776|t=2020. Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK |pdf=|usr=}}
| + | |
| − | {{tp|p=32164708|t=2020. What further should be done to control COVID-19 outbreaks in addition to cases isolation and contact tracing measures?|pdf=|usr=}}
| + | |
| − | {{tp|p=C7154065|t=2020. Methodological challenges of analysing COVID-19 data during the pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32331516|t=2020. Can mathematical modelling solve the current Covid-19 crisis?|pdf=|usr=}}
| + | |
| − | {{tp|p=32238182|t=2020. The fiscal value of human lives lost from coronavirus disease (COVID-19) in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32341002|t=2020. Mitigating the wider health effects of covid-19 pandemic response |pdf=|usr=}}
| + | |
